232 related articles for article (PubMed ID: 34889372)
21. Transplantation in CML in the TKI era: who, when, and how?
Niederwieser C; Kröger N
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):114-122. PubMed ID: 36485123
[TBL] [Abstract][Full Text] [Related]
22. Accelerated-phase CML: de novo and transformed.
Shanmuganathan N; Hughes TP
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):459-468. PubMed ID: 38066863
[TBL] [Abstract][Full Text] [Related]
23. Management of CML-blast crisis.
Hehlmann R; Saußele S; Voskanyan A; Silver RT
Best Pract Res Clin Haematol; 2016 Sep; 29(3):295-307. PubMed ID: 27839570
[TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.
Bar M; Radich J
J Natl Compr Canc Netw; 2013 Mar; 11(3):308-15. PubMed ID: 23486457
[TBL] [Abstract][Full Text] [Related]
25. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Copland M
Br J Haematol; 2022 Dec; 199(5):665-678. PubMed ID: 35866251
[TBL] [Abstract][Full Text] [Related]
26. [Molecular biology and treatment of CML].
Kimura S
Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
[TBL] [Abstract][Full Text] [Related]
27. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Shao C; Wang W; Zuo Z; Mou X; Hu SJ; DiGiuseppe JA; Zu Y; Medeiros LJ; Hu S
Leukemia; 2017 Mar; 31(3):585-592. PubMed ID: 27560111
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis.
Jiang H; Xu LP; Liu DH; Liu KY; Chen SS; Jiang B; Jiang Q; Chen H; Chen YH; Han W; Zhang XH; Wang Y; Wang JZ; Wang FR; Qin YZ; Lai YY; Huang XJ
Bone Marrow Transplant; 2014 Sep; 49(9):1146-54. PubMed ID: 25046218
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
31. B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics.
Yohannan B; George B
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233138
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
33. BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Moiraghi B; Bengió R; Larripa IB
Blood Cells Mol Dis; 2010 Oct; 45(3):192-6. PubMed ID: 20728382
[TBL] [Abstract][Full Text] [Related]
34. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
35. Advanced CML: therapeutic options for patients in accelerated and blast phases.
Shah NP
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S31-S36. PubMed ID: 18397679
[TBL] [Abstract][Full Text] [Related]
36. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
[TBL] [Abstract][Full Text] [Related]
38. Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
Tang K; Lipton JH
Leuk Lymphoma; 2024 Jun; 65(6):705-714. PubMed ID: 38335007
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen-receptor (CAR) engineered natural killer cells in a chronic myeloid leukemia (CML) blast crisis model.
Imeri J; Marcoux P; Huyghe M; Desterke C; Fantacini DMC; Griscelli F; Covas DT; de Souza LEB; Griscelli AB; Turhan AG
Front Immunol; 2023; 14():1309010. PubMed ID: 38259442
[TBL] [Abstract][Full Text] [Related]
40. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
